Neuraceq 300 MBq/mL solution for injection, SODIUM CHLORIDE, Donanemab clinical trials

I5T-MC-AACQ: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease

This study is looking at how different amounts of the drug donanemab affect swelling in the brain (ARIA-E) and reduce amyloid — a protein linked to Alzheimer's disease. It's for adults in the early stages of Alzheimer's.